Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a ...

ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such

Related Keywords

R Michael Gendreau , ,Linkedin ,Nasdaq ,Food Drug Administration ,Twitter ,Exchange Commission ,Facebook ,Virios Therapeutics Inc ,Drug Administration ,Chief Medical Officer ,Securities Litigation Reform Act ,Virios Therapeutic ,Annual Report ,Virios Therapeutics ,Region ,